Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis

Wang,Xuan; Hu,Yue‑Cheng; Zhang,Ru‑Yan; Jin,Dong‑Xia; Jiang,Yuan; Zhang,He‑Nan; Cong,Hong‑Liang

doi:10.3892/etm.2016.3775

Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis

Authors:
- Xuan Wang
- Yue‑Cheng Hu
- Ru‑Yan Zhang
- Dong‑Xia Jin
- Yuan Jiang
- He‑Nan Zhang
- Hong‑Liang Cong
View Affiliations

Affiliations: Cardiology Department, Tianjin Medical University, Tianjin 300070, P.R. China, Cardiology Department, Tianjin Chest Hospital, Tianjin 300222, P.R. China
Published online on: October 4, 2016 https://doi.org/10.3892/etm.2016.3775
Pages: 3242-3248
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of cyclosporin A (CSA) intervention on the immunological mechanisms underlying coronary heart disease (CHD) and restenosis (RS) in rabbits. A total of 48 rabbits were randomly divided into normal control (N), N + CSA, CHD model, CHD + CSA, RS model and RS + CSA groups. Rabbits in the respective groups received different treatments prior to sacrifice at the end of week 12. Iliac arteries were harvested from the rabbits for morphological analysis and to determine the mRNA and protein expression levels of cluster of differentiation (CD) 40/CD40 ligand (CD40L), CD134/CD134 ligand (CD134L) and inflammatory factors, including matrix metalloproteinase (MMP)‑1, MMP‑9, vascular cell adhesion protein (VCAM)‑1, interleukin (IL)‑6 and tumor necrosis factor (TNF)‑α, by reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining. As compared with the N group, the mRNA expression levels of MMP‑9, VCAM‑1 and TNF‑α were significantly increased in the CHD and RS groups (P<0.05), but were significantly decreased in the groups with CSA intervention, as compared with those without CSA intervention (P<0.05). Conversely, there were no significant differences in the expression levels of MMP‑1 and IL‑6 among the six groups, although a decreasing trend of IL‑6 expression was observed following intervention with CSA. Furthermore, there were significant differences in the mRNA and protein expression levels of CD40/CD40L and CD134/CD134L among the N, CHD and RS groups (P<0.05), and between the groups with and without CSA intervention. The present study demonstrated that CSA intervention exerted beneficial effects on CHD and RS, and further studies are required to investigate the mechanisms underlying the effects of CSA on CHD.

View Figures

View References

1	Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr and Sowers JR: Diabetes and cardiovascular disease: A statement for healthcare professionals from the American heart association. Circulation. 100:1134–1146. 1999. View Article : Google Scholar : PubMed/NCBI
2	DeFeudis FV: Coronary atherosclerosis: Current therapeutic approaches and future trends. Life Sci. 49:689–705. 1991. View Article : Google Scholar : PubMed/NCBI
3	Hansson GK and Libby P: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 6:508–519. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lamb DJ, Eales LJ and Ferns GA: Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis. 143:105–113. 1999. View Article : Google Scholar : PubMed/NCBI
5	Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W and Witztum JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:883–887. 1992. View Article : Google Scholar : PubMed/NCBI
6	Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 21:1876–1890. 2001. View Article : Google Scholar : PubMed/NCBI
7	Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, Wijnands E, Goossens P, van Kruchten R, Thevissen L, Boon L, et al: Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 116:4317–4327. 2010. View Article : Google Scholar : PubMed/NCBI
8	Schönbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P and Libby P: Expression of stromelysin-3 in atheorsclerotic lesions: Regulation via CD40-CD40Ligand signaling in vitro and in vivo. J Exp Med. 189:843–853. 1999. View Article : Google Scholar : PubMed/NCBI
9	Schönbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR and Libby P: CD40Ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 156:7–14. 2000. View Article : Google Scholar : PubMed/NCBI
10	Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F and Gurny R: Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm. 56:307–318. 2003. View Article : Google Scholar : PubMed/NCBI
11	Noble S and Markham A: Cyclosporin: A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation. Drugs. 50:924–941. 1995. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Muehlschlegel JD: Closing the pore on reperfusion injury: Myocardial protection with cyclosporine. Anesthesiology. 121:212–213. 2014. View Article : Google Scholar : PubMed/NCBI
14	Sazliyana S, Shahrir MS Mohd, Kong CT, Tan HJ, Hamidon BB and Azmi MT: Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus. 20:1260–1266. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis JD, Sparks JD and Berk BC: Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 208:53–66. 2011. View Article : Google Scholar : PubMed/NCBI
16	Poston RN, Haskard DO, Coucher JR, Gall NP and Johnson-Tidey RR: Expression of intercellular adhesion molecule-1 in atherosclerotic Plaques. Am J Pathol. 140:665–673. 1992.PubMed/NCBI
17	Zeitler H, Ko Y, Zimmermann C, Nickenig G, Glänzer K, Walger P, Sachinidis A and Vetter H: Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur J Med Res. 2:389–394. 1997.PubMed/NCBI
18	Bou Khzam L, Boulahya R, Abou-Saleh H, Hachem A, Zaid Y and Merhi Y: Soluble CD40 ligand stimulates the pro-angiogenic function of peripheral blood angiogenic outgrowth cells via increased release of matrix metalloproteinase-9. PLoS One. 8:e842892013. View Article : Google Scholar : PubMed/NCBI
19	Ll H, Cybulsdy MI, Gimbrone MA Jr and Libby P: Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 143:1551–1559. 1993.PubMed/NCBI
20	Smart EJ, Ying Y, Donzell WC and Anderson RG: A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem. 271:29427–29435. 1996. View Article : Google Scholar : PubMed/NCBI
21	Hu J, Zhang Z, Shen WJ and Azhar S: Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond). 7:472010. View Article : Google Scholar : PubMed/NCBI
22	Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, et al: Inflammatory profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine. 60:681–685. 2012. View Article : Google Scholar : PubMed/NCBI
23	Joo YH, Chang DY, Kim JH, Jung MH, Lee J, Cho HJ, Jeon SY, Kim SJ and Kim SW: Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model. Int Forum Allergy Rhinol. 2016. View Article : Google Scholar
24	Massuda TY, Nagashima LA, Leonello PC, Kaminami MS, Mantovani MS, Sano A, Uno J, Venancio EJ, Camargo ZP and Itano EN: Cyclosporin A treatment and decreased fungal load/antigenemia in experimental murine paracoccidioidomycosis. Mycopathologia. 171:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
25	Houssen ME, Haron MM, Metwally SS and Ibrahim TM: Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis. J Physiol Biochem. 67:115–120. 2011. View Article : Google Scholar : PubMed/NCBI
26	Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 23:23–68. 2005. View Article : Google Scholar : PubMed/NCBI
27	Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS and Stefanadis C: The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J Am Coll Cardiol. 54:669–677. 2009. View Article : Google Scholar : PubMed/NCBI
28	Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, et al: CD40Ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 115:1571–1580. 2007. View Article : Google Scholar : PubMed/NCBI
29	Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J and Kuiper J: Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 112:1054–1062. 2005. View Article : Google Scholar : PubMed/NCBI
30	Lee TS, Yen HC, Pan CC and Chau LY: The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 19:734–742. 1999. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, Samnegård A, Petros C, Rollins J, Bennet AM, Wiman B, et al: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet. 37:365–372. 2005. View Article : Google Scholar : PubMed/NCBI
32	Gupta AK, Giaglis S, Hasler P and Hahn S: Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PLoS One. 9:e970882014. View Article : Google Scholar : PubMed/NCBI
33	Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, et al: Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 55:1200–1205. 2010. View Article : Google Scholar : PubMed/NCBI
34	Dąbrowski MJ: Is further improvement of the treatment of acute coronary syndromes still possible. Postepy Kardiol Interwencyjnej. 9:41–44. 2013.PubMed/NCBI